[Alpha Biz=(Chicago) Reporter Paul Lee] Daewoong Pharmaceutical announced on the 27th that its sales and operating profit were tentatively estimated at 307.1 billion won and 36.2 billion won, respectively, in the second quarter of this year.
Sales rose 4.5% year-on-year, and operating profit grew 7.8% over the same period. Net profit for the current term was 28.8 billion won, up 38.7% from the same period last year.
Daewoong Pharmaceutical's recently released new drug has increased sales. It is also said that it has generated 41 billion won in sales in just one year after the domestic launch of the gastroesophageal reflux disease treatment.
Daewoong Pharmaceutical launched an SGLT-2 inhibitor in May, and a month later, metformin compound Enblomet was also approved. Nabota is currently supplied to the United States, the United Kingdom, Germany, Austria and Italy.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
